Page 142 - Read Online

Santiago et al. J Transl Genet Genom 2021;5:380-95 https://dx.doi.org/10.20517/jtgg.2021.16 Page 394

2013;45:242-52. DOI PubMed PMC
65. Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 2015;125:3988-95.
DOI PubMed PMC
66. Churchman ML, Qian M, Te Kronnie G, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic
leukemia. Cancer Cell 2018;33:937-48.e8. DOI PubMed PMC
67. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic
leukemia and risk of relapse. Nat Genet 2013;45:1494-8. DOI PubMed PMC
68. Walsh KM, de Smith AJ, Chokkalingam AP, et al. Novel childhood ALL susceptibility locus BMI1-PIP4K2A is specifically
associated with the hyperdiploid subtype. Blood 2013;121:4808-9. DOI PubMed PMC
69. Ellinghaus E, Stanulla M, Richter G, et al. Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute
lymphoblastic leukemia. Leukemia 2012;26:902-9. DOI PubMed PMC
70. Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children
with acute lymphoblastic leukemia. J Clin Oncol 2015;33:1235-42. DOI PubMed PMC
71. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl
J Med 2018;378:439-48. DOI PubMed PMC
72. O'brien MM, Ji L, Shah NN, et al. A Phase 2 Trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or
refractory (R/R) CD22+ B-acute lymphoblastic leukemia (B-ALL): results from Children's Oncology Group Protocol AALL1621.
Blood 2019;134:741. DOI
73. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free
survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical
trial. JAMA 2021;325:833-42. DOI PubMed PMC
74. Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute
lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010;28:4755-61. DOI PubMed PMC
75. Biondi A, Gandemer V, De Lorenzo P, et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic
leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol 2018;5:e641-52. DOI
PubMed
76. Schultz KR, Carroll A, Heerema NA, et al; Children’s Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia
chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014;28:1467-71.
DOI PubMed PMC
77. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive
acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009;27:5175-81. DOI PubMed PMC
78. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-
chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol
2012;13:936-45. DOI PubMed PMC
79. Hunger SP, Saha V, Devidas M, et al. CA180-372: An International Collaborative Phase 2 Trial of dasatinib and chemotherapy in
pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood
2017;130:98-98. DOI
80. Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with
philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0622. J Clin
Oncol 2018;36:2306-14. DOI PubMed PMC
81. Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute
lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol 2020;6:358-66. DOI PubMed PMC
82. Foà R, Bassan R, Vitale A, et al; GIMEMA Investigators. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in
adults. N Engl J Med 2020;383:1613-23. DOI PubMed
83. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute
lymphoblastic leukemia. Cancer Cell 2012;22:153-66. DOI PubMed PMC
84. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic
leukemia. Blood 2012;120:3510-8. DOI PubMed PMC
85. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged
B-precursor acute lymphoblastic leukemia. Blood 2012;120:833-42. DOI PubMed PMC
86. Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class
rearrangements. Blood 2019;134:1351-5. DOI PubMed
87. Ding YY, Stern JW, Jubelirer TF, et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-
like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica 2018;103:e427-31. DOI
PubMed PMC
88. Cario G, Leoni V, Conter V, et al. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-
class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica
2020;105:1887-94. DOI PubMed PMC
89. Roberts KG, Janke LJ, Zhao Y, et al. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective
TRK inhibition. Blood 2018;132:861-5. DOI PubMed PMC
90. Nardi V, Ku N, Frigault MJ, et al. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-